NDAORALSYRUP
Approved
Mar 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
PERIACTIN (cyproheptadine hydrochloride) by Merck & Co. is clinical pharmacology cyproheptadine is a serotonin and histamine antagonist with anticholinergic and sedative effects. First approved in 1962.
Drug data last refreshed 57m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PERIACTIN (cyproheptadine hydrochloride) is an oral syrup formulation combining serotonin and histamine antagonist activity with anticholinergic and sedative properties. It competes with serotonin and histamine at receptor sites, enabling use across allergic and appetite-related conditions. The drug has been marketed since 1962 and represents a legacy mechanism with multi-decade clinical utility.
LOE Approaching
LOE-approaching lifecycle with moderate competitive pressure (30%) suggests diminishing brand investment and team contraction; legacy product maintenance likely dominates over growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Cyproheptadine is a serotonin and histamine antagonist with anticholinergic and sedative effects. Antiserotonin and antihistamine drugs appear to compete with serotonin and histamine, respectively, for receptor sites. Pharmacokinetics and Metabolism After a single 4 mg oral…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PERIACTIN offers limited career growth given its LOE-approaching lifecycle and minimal linked job postings; opportunities center on cost management, market access, and legacy patient support rather than innovation or expansion. This is a stable, non-growth role suited for professionals seeking operational expertise in mature product management.
Worked on PERIACTIN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.